Delay in handling patients with Acute ST-elevation myocardial infarction (STEMI) is the cause of high mortality and the incidence of MACE (Major Adverse Cardiac Event), so efforts are needed to reduce it by handling patients with Acute Coronary Syndrome (ACS) with the implementation of clinical pathways. This study evaluates the application of clinical pathways for ACS STEMI patients based on content and quality and evaluates the effectiveness of clinical pathways based on length of stay, total costs, and outcomes between ACS STEMI patients with clinical pathways and nonclinical pathways. This research uses mixed methods with an exploratory sequential approach. Evaluation of clinical pathways for ACS STEMI patients with a qualitative approach through in-depth interviews using the Integrated Care Pathway Appraisal Tool (ICPAT) questionnaire. Furthermore, a comparative approach is used to determine the effectiveness of clinical pathways based on length of stay, total costs and outcomes (outcomes) between ACS STEMI patients who have and do not have a clinical pathway. The study was conducted from November 2021 to April 2022 at the